Revenue from Contract with Customer [Text Block]

Revenue

Disaggregation of revenue

Disaggregated revenue by primary geographical markets and major goods and service lines are as follows:


	Reportable Segments
	Three Months Ended
	June 29, 2025						June 30, 2024
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	197,071	$	126,509	$	323,580	$	189,790	$	117,993	$	307,783
Europe	84,298		119,334		203,632		74,552		110,036		184,588
Asia	84,529		108,543		193,072		84,183		115,131		199,314
	$	365,898	$	354,386	$	720,284	$	348,525	$	343,160	$	691,685

Major goods/service lines
Life Sciences Solutions	$	298,052	$	—	$	298,052	$	297,782	$	—	$	297,782
Software	67,846		—		67,846		50,743		—		50,743
Immunodiagnostics	—		218,818		218,818		—		213,252		213,252
Reproductive health	—		135,568		135,568		—		129,908		129,908
	$	365,898	$	354,386	$	720,284	$	348,525	$	343,160	$	691,685


	Reportable Segments
	Six Months Ended
	June 29, 2025						June 30, 2024
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	381,350	$	246,859	$	628,209	$	366,367	$	235,770	$	602,137
Europe	160,320		225,104		385,424		152,008		211,142		363,150
Asia	164,623		206,790		371,413		166,664		209,654		376,318
	$	706,293	$	678,753	$	1,385,046	$	685,039	$	656,566	$	1,341,605

Major goods/service lines
Life Sciences Solutions	$	584,505	$	—	$	584,505	$	589,394	$	—	$	589,394
Software	121,788		—		121,788		95,645		—		95,645
Immunodiagnostics	—		416,380		416,380		—		401,913		401,913
Reproductive health	—		262,373		262,373		—		254,653		254,653
	$	706,293	$	678,753	$	1,385,046	$	685,039	$	656,566	$	1,341,605

Contract Balances

Unbilled receivable and Contract assets: The timing of revenue recognition may differ from the timing of customer billing. When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets. The unbilled receivables are classified as either current in “Accounts receivable, net” or as long-term in “Other assets, net” in the condensed consolidated balance sheets. Unbilled receivables totaled $91.1 million and $80.6 million at June 29, 2025 and December 29, 2024, respectively, primarily related to the Life Sciences software business. The Company had no material contract assets as of June 29, 2025 and December 29, 2024.

Deferred revenue and Customer deposits: Deferred revenue is recorded when revenue is recognized subsequent to customer invoicing. Deferred revenue is classified as either current in “Accrued expenses and other current liabilities” or as long-term in “Other long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. Substantially all of the deferred revenue is expected to be recognized in revenue within 12 months of the balance sheet date, and has been classified within accrued expenses and other current liabilities. The deferred revenue balance is primarily related to the Company’s software as a service offerings, maintenance contracts and prepaid storage arrangements. Deferred revenue totaled $225.3 million and $212.8 million at June 29, 2025 and December 29, 2024, respectively. The Company also had customer deposits received in advance of the transfer of control totaling $19.0 million and $19.5 million at June 29, 2025 and December 29, 2024, respectively. The Company expects that these customer deposits will be recognized in revenue within three months of the balance sheet date.

Transaction price allocated to the remaining performance obligations

The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.